SEC-sourced researchBeta
CLDX
Celldex Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0000744218
- Exchange
- Nasdaq
- Business activity
- — · SIC 2835
- Financial inputs
- 6/6
- Filing date
- Oct 7, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 6,883,000.0000 | Feb 25, 2026 |
| December 2024 | 7,020,000.0000 | Feb 25, 2026 |
| December 2025 | 1,545,000.0000 | Feb 25, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 1,545,000.0000 | -258,757,000.0000 | -210,945,000.0000 | 582,983,000.0000 | 55,818,000.0000 | Feb 25, 2026 |
| December 2024 | 7,020,000.0000 | -157,863,000.0000 | -157,778,000.0000 | 792,340,000.0000 | 45,335,000.0000 | Feb 25, 2026 |
| December 2023 | 6,883,000.0000 | -141,429,000.0000 | -107,291,000.0000 | — | — | Feb 25, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.55M | December 2025 | Feb 25, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $7.02M | December 2024 | Feb 25, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$258.76M | December 2025 | Feb 25, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$210.95M | December 2025 | Feb 25, 2026 | 10-K |
| Total assetsAssets | $582.98M | December 2025 | Feb 25, 2026 | 10-K |
| Total liabilitiesLiabilities | $55.82M | December 2025 | Feb 25, 2026 | 10-K |